(Q30857433)

27 June 2017

1 reference

title

Dovitinib: rationale, preclinical and early clinical data in urothelial carcinoma of the bladder (English)

1 reference

27 June 2017

Clarisse R Mazzola

1

0 references

author name string

Khurram M Siddiqui

series ordinal

2

1 reference

27 June 2017

Michele Billia

series ordinal

3

1 reference

27 June 2017

Joseph Chin

series ordinal

4

1 reference

27 June 2017

language of work or name

English

0 references

publication date

4 October 2014

1 reference

Expert Opinion on Investigational Drugs

27 June 2017

1 reference

27 June 2017

23

1 reference

27 June 2017

1553-1562

1 reference

27 June 2017

11

1 reference

27 June 2017

Cancer statistics, 2014

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.966900

Epidemiology and risk factors of urothelial bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.966900

Adjuvant cisplatin plus methotrexate versus methotrexate, vinblastine, epirubicin, and cisplatin in locally advanced bladder cancer: results of a randomized, multicenter, phase III trial (AUO-AB 05/95).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.966900

Superficial and muscle-invasive bladder cancer: principles of management for outcomes assessments.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.966900

Radical cystectomy for the treatment of T1 bladder cancer: the Canadian Bladder Cancer Network experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.966900

EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.966900

EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.966900

New therapeutic challenges in advanced bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.966900

ICUD-EAU International Consultation on Bladder Cancer 2012: Non-muscle-invasive urothelial carcinoma of the bladder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.966900

ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.966900

Incidence, survival and mortality rates of stage-specific bladder cancer in United States: a trend analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.966900

Combined gene expression and genomic profiling define two intrinsic molecular subtypes of urothelial carcinoma and gene signatures for molecular grading and outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.966900

Integrated genomic and gene expression profiling identifies two major genomic circuits in urothelial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.966900

A systematic study of gene mutations in urothelial carcinoma; inactivating mutations in TSC2 and PIK3R1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.966900

A molecular taxonomy for urothelial carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.966900

Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.966900

Targeting p53 for Novel Anticancer Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.966900

Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.966900

Chromosomal changes in uroepithelial carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.966900

Molecular pathways in invasive bladder cancer: new insights into mechanisms, progression, and target identification

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.966900

Molecular pathways of urothelial development and bladder tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.966900

Comprehensive molecular characterization of urothelial bladder carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.966900

Emerging drugs for urothelial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.966900

Phase II study of gemcitabine, carboplatin, and bevacizumab in patients with advanced unresectable or metastatic urothelial cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.966900

Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.966900

Phase II study of sunitinib in patients with metastatic urothelial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.966900

Gemcitabine, Cisplatin, and sunitinib for metastatic urothelial carcinoma and as preoperative therapy for muscle-invasive bladder cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.966900

Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04-75.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.966900

Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.966900

A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II Consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.966900

Phase 2 trial of sorafenib in patients with advanced urothelial cancer: a trial of the Eastern Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.966900

Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.966900

Combined treatment with pazopanib and vinflunine in patients with advanced urothelial carcinoma refractory after first-line therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.966900

Phase II study of Aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial cancer, a California Cancer Consortium Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.966900

Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.966900

Results of the Southwest Oncology Group phase II evaluation (study S0031) of ZD1839 for advanced transitional cell carcinoma of the urothelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.966900

A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: results of Cancer and Leukemia Group B (CALGB) 90102.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.966900

A phase II trial of neoadjuvant erlotinib in patients with muscle-invasive bladder cancer undergoing radical cystectomy: clinical and pathological results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.966900

Phase II trial of cetuximab with or without paclitaxel in patients with advanced urothelial tract carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.966900

Target-specific, histology-independent, randomized discontinuation study of lapatinib in patients with HER2-amplified solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.966900

A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.966900

Phase II study of everolimus in metastatic urothelial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.966900

A phase II trial of neoadjuvant nab-paclitaxel, carboplatin, and gemcitabine (ACaG) in patients with locally advanced carcinoma of the bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.966900

A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.966900

Nanoparticle albumin-bound paclitaxel for second-line treatment of metastatic urothelial carcinoma: a single group, multicentre, phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.966900

A gene encoding a fibroblast growth factor receptor isolated from the Huntington disease gene region of human chromosome 4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.966900

Genomic organization of the human fibroblast growth factor receptor 3 (FGFR3) gene and comparative sequence analysis with the mouse Fgfr3 gene.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.966900

Fibroblast growth factors, their receptors and signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.966900

Mapping ligand binding domains in chimeric fibroblast growth factor receptor molecules. Multiple regions determine ligand binding specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.966900

A novel alternatively spliced fibroblast growth factor receptor 3 isoform lacking the acid box domain is expressed during chondrogenic differentiation of ATDC5 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.966900

The choice between alternative IIIb and IIIc exons of the FGFR-3 gene is not strictly tissue-specific

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.966900

Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.966900

Stimulation of phosphatidylinositol 3-kinase by fibroblast growth factor receptors is mediated by coordinated recruitment of multiple docking proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.966900

FRS2 proteins recruit intracellular signaling pathways by binding to diverse targets on fibroblast growth factor and nerve growth factor receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.966900

Cell responses to FGFR3 signalling: growth, differentiation and apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.966900

Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.966900

Fibroblast growth factor receptor-3 in urothelial tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.966900

Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.966900

FGFR3 mutations and a normal CK20 staining pattern define low-grade noninvasive urothelial bladder tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.966900

Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.966900

Knockdown by shRNA identifies S249C mutant FGFR3 as a potential therapeutic target in bladder cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.966900

Fibroblast growth factor receptor 3 is a rational therapeutic target in bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.966900

CDKN2A homozygous deletion is associated with muscle invasion in FGFR3-mutated urothelial bladder carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.966900

FGFR3 mutations indicate better survival in invasive upper urinary tract and bladder tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.966900

FGFR3 and P53 characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.966900

FGFR3 and p53 protein expressions in patients with pTa and pT1 urothelial bladder cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.966900

Oncogenic properties of the mutated forms of fibroblast growth factor receptor 3b.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.966900

FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.966900

Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.966900

Generation of monoclonal antibody targeting fibroblast growth factor receptor 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.966900

Targeting the extracellular domain of fibroblast growth factor receptor 3 with human single-chain Fv antibodies inhibits bladder carcinoma cell line proliferation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.966900

Antitumor activity of fibroblast growth factor receptor 3-specific immunotoxins in a xenograft mouse model of bladder carcinoma is mediated by apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.966900

Fibroblast growth factor signalling: from development to cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.966900

Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.966900

Epithelial mesenchymal transition status is associated with anti-cancer responses towards receptor tyrosine-kinase inhibition by dovitinib in human bladder cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.966900

Dovitinib induces apoptosis and overcomes sorafenib resistance in hepatocellular carcinoma through SHP-1-mediated inhibition of STAT3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.966900

The anticancer multi-kinase inhibitor dovitinib also targets topoisomerase I and topoisomerase II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.966900

Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.966900

A phase I pharmacokinetic and pharmacodynamic study of TKI258, an oral, multitargeted receptor tyrosine kinase inhibitor in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.966900

Phase I study of dovitinib (TKI258), an oral FGFR, VEGFR, and PDGFR inhibitor, in advanced or metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.966900

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.966900

FGFR3-targeted mAb therapy for bladder cancer and multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.966900

Targeted therapies in bladder cancer--an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.966900

10.1517/13543784.2014.966900

21 January 2018

Identifiers

DOI

1 reference

27 June 2017

1 reference